Human-Albumin, Salzarm Behring

Human-Albumin, Salzarm Behring is a sterile solution for injection that contains human serum albumin as the active pharmaceutical ingredient. The product is supplied in an unspecified strength and is marketed in the European Union as a prescription‑only plasma volume expander. It is used to restore intravascular oncotic pressure and to support patients with reduced plasma protein levels in a variety of clinical settings.

Human-Albumin, Salzarm Behring is indicated for clinical situations where rapid expansion of plasma volume or correction of low albumin levels is required.

- Treatment of hypovolemia associated with trauma, surgery, or dehydration. - Management of hypoalbuminemia in patients with liver disease, nephrotic syndrome, or malnutrition. - Supportive care for severe burns to maintain circulating volume. - Adjunct therapy in septic or hemorrhagic shock to improve hemodynamics. - Use during cardiopulmonary bypass or extracorporeal circulation to prevent fluid shifts.

Adverse reactions to Human-Albumin, Salzarm Behring are generally related to the infusion process or to immune‑mediated responses.

Common: - Mild fever or chills during or shortly after infusion. - Transient hypotension or hypertension. - Localized erythema or pruritus at the infusion site. - Headache or dizziness occurring during administration.

Serious: - Anaphylactic or severe allergic reactions, including bronchospasm and angioedema. - Acute hemolysis or renal impairment linked to rapid volume shifts. - Transmission‑related infections, although rare, due to plasma-derived product.

When prescribing Human-Albumin, Salzarm Behring, clinicians should consider several safety aspects to minimize risk.

- Verify patient history for known albumin or plasma product hypersensitivity. - Assess fluid status and cardiac function before infusion to avoid overload. - Use a controlled infusion rate; rapid administration may provoke hypotension. - Monitor vital signs and laboratory parameters (e.g., serum albumin, electrolytes) during therapy. - Avoid use in patients with severe congestive heart failure unless benefits outweigh risks. - Document lot numbers and traceability in case of adverse event reporting.

Human-Albumin, Salzarm Behring may influence the pharmacokinetics of other intravenously administered agents, and certain co‑medications can increase the likelihood of infusion reactions.

Avoid: - Concurrent administration of other plasma‑derived products without appropriate monitoring. - Use with high‑dose diuretics that may exacerbate intravascular volume depletion. - Simultaneous infusion of vesicant chemotherapy agents that could increase local tissue injury.

Use with caution: - Co‑administration of vasopressors, as volume expansion may alter their dosing requirements. - Concurrent use of anticoagulants; monitor coagulation parameters due to dilutional effects. - Administration alongside immunosuppressants, which may mask early signs of allergic reactions.